We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 04, 2022

Natalizumab Effective for Achieving NEDA-3 in Adolescents With MS

Journal of the Neurological Sciences


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the Neurological Sciences
Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage
J. Neurol. Sci. 2022 Jan 15;432(xx)120074, S Menascu, A Fattal-Valevski, A Vaknin-Dembinsky, R Milo, K Geva, D Magalashvili, M Dolev, S Flecther, A Kalron, S Miron, C Hoffmann, R Aloni, M Gurevich, A Achiron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading